Metabotropic glutamate receptor 5: a target for migraine therapy

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Hong Sun et al.   LANCET NEUROLOGY

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

(2015) Theo Vos et al.   LANCET

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Incredible progress for an era of better migraine care

(2015) Peter J. Goadsby   Nature Reviews Neurology

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

(2014) David W Dodick et al.   LANCET NEUROLOGY

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

(2014) David W Dodick et al.   LANCET NEUROLOGY

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias

(2014) Olivier Rascol et al.   PARKINSONISM & RELATED DISORDERS

Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks

(2013) Baltazar Gomez-Mancilla et al.   CEPHALALGIA

Peripheral Metabotropic Glutamate Receptor Subtype 5 Contributes to Inflammation-Induced Hypersensitivity of the Rat Temporomandibular Joint

(2013) Bo Li et al.   JOURNAL OF MOLECULAR NEUROSCIENCE

Endocannabinoids in the Brainstem Modulate Dural Trigeminovascular Nociceptive Traffic via CB1 and "Triptan" Receptors: Implications in Migraine

(2013) S. Akerman et al.   JOURNAL OF NEUROSCIENCE

Acid-sensing ion channel 1: A novel therapeutic target for migraine with aura

(2012) Philip R. Holland et al.   ANNALS OF NEUROLOGY

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study

(2012) Markus Färkkilä et al.   LANCET NEUROLOGY

Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease

(2011) F. Zerbib et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?

(2010) Juana CA Marin et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Current practice and future directions in the prevention and acute management of migraine

(2010) Peter J Goadsby et al.   LANCET NEUROLOGY

CGRP and its receptors provide new insights into migraine pathophysiology

(2010) Tony W. Ho et al.   Nature Reviews Neurology

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

(2008) Tony W Ho et al.   LANCET